b'Board of DirectorsRight skills, right experience,right peopleDr Mark PaytonChief Executive OfficerDate of appointment: December 2014 Following his time at OUI Mark was the vice Experience: Mark has extensive privatepresident corporate development at Oxxon investment and scale-up experience. SinceTherapeutics Inc, prior to its sale to Oxford co-founding Mercia he has led the sales of BioMedica plc. He gained his PhD jointly between Hybrid Systems (to Myotec) to create PsiOxusthe University of Oxford and the University of 01 Therapeutics Ltd, Warwick Effect Polymers Ltd London (Kings College). Mark also has an MBA (to Polytherics Ltd) to create Abzena plc and ledfrom the University of Warwick, is a Sainsbury the founding investment in Allinea Software LtdManagement Fellow for Life Sciences and was (sold to ARM). Prior to Mercia, Mark played aawarded the 2015 EY Entrepreneur of the Year leading role within Oxford University Innovation(regional and national).(OUI, the technology transfer operation of theExternal appointments: NoneUniversity of Oxford), spinning out BioAnalab (sold to Millipore), Oxford Immunotec (listedon NASDAQ), Oxitec (sold to Intrexon) andNatural Motion (sold to Zynga).Martin GlanfieldChief Financial OfficerDate of appointment: December 2014 The group was successfully restructured andExperience: Martin has significant public marketssold within 12 months to a NASDAQ listed US and business experience. He is a KPMG qualifiedelectronics group, whereupon he became a vice chartered accountant with more than 20 yearspresident, working frequently in Silicon Valley. He experience as chief financial officer of listed,was chief executive of the private equity business 02 private equity-backed and privately ownedForward Group plc from 2003 to 2005 and since technology-led businesses. Martin joined thethen has been group finance and IT director ofmain market listed Forward Group PLC in 1993the large international food processing group and was group financial director from 1995 untilBoparan Holdings Ltd and a private equity-its sale for 129.0million in 1997. In 1999, asbacked building services business. Martin has an deputy chief executive of Symonds plc, Martin ledhonours degree in business from Aston University. the public to private of this main market listedExternal appointments: Nonetechnology group, backed by NatWest Equity Partners. Julian ViggarsChief Investment OfficerDate of appointment: April 2018 Alongside his wide experience of investing across Experience: Julian joined Mercia through themany sectors, Julian is fund manager for the 2016 acquisition of Enterprise Ventures, which Northern Powerhouse Investment Fund (NPIF), he joined in 2004 and was head of technologythe RisingStars Growth Funds and the Finance investments at the time of its acquisition. He Yorkshire Seedcorn Fund. Julian played a leading 03 has over 20 years of venture capital experience,role in securing the managed funds contracts including the successful listings of companiesawarded by the British Business Bank and North such as Blue Prism Group plc and OptiBiotixEast Fund Ltd and has been Mercias Chief Health plc. Through the subsequent sell down ofInvestment Officer since April 2018. Julian hasits holding in Blue Prism, Mercias RisingStarsa geology with chemistry degree from the Growth Fund realised c95m, 105x the cost of itsUniversity of Southampton and qualified asinvestment. Julian leads the equity investmenta chartered accountant with accountantsteam as well as managing the pipeline of MerciasSmith & Williamson. direct investments.External appointments: None56 Mercia Asset Management PLCAnnual Report and Accounts 2020'